EPRX NASDAQ
Eupraxia Pharmaceuticals Inc.
1W: -9.6%
1M: -2.8%
3M: +11.0%
YTD: -4.4%
1Y: +19.3%
$7.24
-0.59 (-7.54%)
Weekly Expected Move ±12.5%
$5
$6
$7
$8
$9
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$332K
+0.0% ▲
Operating Income
-$54M
-38.2% ▼
Net Income
-$54M
-46.9% ▼
EPS (Diluted)
$-1.44
-89.5% ▼
EBITDA
-$53M
-48.5% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $332K |
| Gross Profit | $0 | $0 | $0 | $0 | -$332K |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $8M | $14M | $20M | $23M | $30M |
| SG&A Expenses | $7M | $4M | $7M | $16M | $24M |
| Operating Expenses | $15M | $18M | $28M | $39M | $53M |
| Operating Income | -$15M | -$18M | -$28M | -$39M | -$54M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $1M | $983K | $1M | $868K | $0 |
| Income Before Tax | -$18M | -$19M | -$29M | -$37M | -$54M |
| Tax Expense | $0 | $0 | $36K | $3K | $27K |
| Net Income | -$18M | -$18M | -$28M | -$37M | -$54M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-1.61 | $-0.96 | $-1.17 | $-0.76 | $-1.44 |
| EBITDA | -$17M | -$18M | -$28M | -$36M | -$53M |
| Shares Outstanding | 14M | 19M | 24M | 34M | 40M |